Study Reveals COVID-19 Pathway From the Oral Cavity to Lungs
Compared to other risk factors, periodontal diseases and poor oral hygiene may be more accurate predictors of COVID-19 severity, a new study has found.
Author
Researchers Suggest Gene-Based Therapy May Help Regenerate Teeth
As adults live longer, demand for dental implants continues to grow.
The Esther Wilkins Lifetime Achievement Award
The 2020/2021 recipient of the Esther Wilkins Lifetime Achievement Award, sponsored by Colgate Oral Pharmaceuticals, Inc., is announced.
The Staying Power of Fluoride Varnish
Fluoride varnish has become a widely utilized, professional topical application for treating dentinal hypersensitivity and preventing caries. While fluoride varnish has United States Food and Drug Administration approval for treating…
New Wiki on Human Salivary Proteins May Transform Diagnostic Testing
An article published in the Journal of Dental Research provides a database that curates information on proteins in saliva.
Crest+Oral-B, The Smile Generation, and PDS Foundation to Host Webinar on June 25
Live event to highlight how good oral health can reduce the risks of deteriorating brain health.
Head and Neck Cancer Cells Hijack Nearby Healthy Tissue
University of Michigan School of Dentistry scientists have identified a mechanism by which head and neck cancer cells subvert adjacent normal tissue.
Philips and United Concordia Dental Enter Agreement
A new agreement between Phillips and United Concordia Dental will provide unique access to select Philips Sonicare oral healthcare products for employers and brokers who currently work with the national dental solutions partner.
Oral Health Professionals and Infectious Disease Status
The United States Centers for Disease Control and Prevention (CDC) characterizes an exposure-prone procedure as any that poses a risk of percutaneous injury to providers due to limited visibility or confinement within an anatomical site.…
Rutgers Receives FDA Approval for Cancer Therapy Clinical Trials
Actinobac Biomed, a company founded by Rutgers School of Dental Medicine researcher Scott Kachlany, PhD, has received U.S. Food and Drug Administration approval to begin a Phase I clinical trial.
